Article Text

Download PDFPDF

5PSQ-119 A new pharmaceutical care programme for COVID-19 patients treated with Paxlovid®: Implementation and safety outcomes reported
  1. M Ferris Villanueva1,
  2. E Chamorro de Vega2,
  3. CG Gonzalez Rodriguez2,
  4. B Torroba Sanz2,
  5. J Vicente Valor2,
  6. A Herranz Alonso2,
  7. M Sanjurjo Sáez2
  1. 1Gregorio Marañón University General Hospital, Hospital Pharmacy, Madrid, Spain
  2. 2Gregorio Marañón General University Hospital, Hospital Pharmacy, Madrid, Spain


Background and Importance The COVID-19 pandemic has highlighted the important role that hospital pharmacists play in improving pharmacotherapy outcomes. Paxlovid® (Nirmatrelvir/ritonavir) was recently granted an Emergency Use Authorisation for the treatment of mild to moderate COVID-19. However, the use of Paxlovid® with certain other drugs in high-risk patients may result in potentially significant drug-drug interactions (DDI) and adverse drug events (ADE).

Aim and Objectives To assess the impact of a comprehensive pharmaceutical care program (CPCP) focusing on the prevention of DDI and ADE, initiated in a hospital pharmacy for patients with mild to moderate COVID-19 treated with Paxlovid®.

Material and Methods Design: Quasi-experimental study performed between 1 May and 31 July 2022. Pharmacists were responsible for proposing COVID-19 local guidelines to physicians, monitoring adherence to guidelines, managing DDI and ADE, providing patient education, and evaluating health outcomes. A telephone consultation was carried out 10 days after the end of Paxlovid® treatment.

Potential DDI were detected according to Lexi-Comp® and Liverpool COVID-19 databases. Paxlovid-related ADE reported were graded according to Common Terminology Criteria for Adverse Events, version 4.

Results 140 patients (60.7% outpatients) initiated Paxlovid® and were enrolled in the CPCP. Adherence to local guidelines for the use of Paxlovid® was 100%.

Overall, 232 DDI were detected in 111 (79.3%) patients, 142 (61.2%) of which required specific management (34.5% discontinuation of the concomitant drug and 65.5% dose adjustment).

Pharmacists made 267 interventions that led to the prevention of 177 ADE (1.3/patient), 96 (54.2%) of which were grade G-H (NCC MERP classification).

At day 10, 96 ADEs were reported in 42 patients (26.1% of which were grade ≥3), being dysgeusia and diarrhoea the most common. Premature discontinuation of Paxlovid® due to ADEs was necessary in 4 (2.8%) patients.

Conclusion and Relevance The implementation of a CPCP developed by hospital pharmacists for patients treated with Paxlovid® was an effective approach for monitoring adherence to guidelines, managing DDI, providing patient education, and evaluating safety outcomes. Paxlovid® showed an acceptable safety profile.

Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.